Mark Zoradi Eric Wold Coronavirus film vaccine Mark Zoradi Eric Wold

Cinemark Analyst Upgrades Stock on "Next Leg of Recovery"

Reading now: 579
hollywoodreporter.com

B. Riley Securities analyst Eric Wold on Friday upgraded his rating on shares of cinema giant Cinemark from "neutral" to "buy" and doubled his stock price target to $28, predicting "attendance should return to 2019 levels by 2023." Following a chat this week withCinemark CEO Mark Zoradi, CFO and COO Sean Gamble and Chanda Brashears, vp of investor relations,about the coronavirus pandemic and the company's outlook, Wold published a report entitled "Virtual 'Fireside Chat' Highlights Underlying Operating Strengths in the Midst of Reopening Uncertainties." "We continue to believe that consumers want to return to theaters when permitted and are optimistic that a more efficient vaccine distribution in the coming months will make that more of a.

Read more on hollywoodreporter.com
The website starsalert.com is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA